FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Raber

Research Profile

Activities & Behaviors

Drug Evaluation

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Heather Carlson; Renato Lenzi; Martin N Raber; Gauri R Varadhachary
A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary.
Martin N Raber
Emerging techniques for determining the tissue of origin in patients with unknown primary carcinoma.
Martin N Raber
Carcinoma of unknown primary origin: on the cusp of a new era.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Raber (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Heather Carlson; Renato Lenzi; Martin N Raber; Gauri R Varadhachary
A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary.
International journal of clinical oncology 2013;18(2):226-31.
2010: Martin N Raber
Emerging techniques for determining the tissue of origin in patients with unknown primary carcinoma.
Expert opinion on medical diagnostics 2010;4(6):455-7.
2010: Martin N Raber
Carcinoma of unknown primary origin: on the cusp of a new era.
Cancer journal (Sudbury, Mass.) 2010;16(1):66-7.
2008: Gauri R Varadhachary; Dmitri Talantov; Martin N Raber; Christina Meng; Kenneth R Hess; Tim Jatkoe; Renato Lenzi; David R Spigel; Yixin Wang; F Anthony Greco; James L Abbruzzese; John D Hainsworth
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(27):4442-8.
2008: Gauri R Varadhachary; Martin N Raber; Aurelio Matamoros; James L Abbruzzese
Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions.
The lancet oncology 2008;9(6):596-9.
2006: Kenneth R Hess; Gauri R Varadhachary; Sarah H Taylor; Wei Wei; Martin N Raber; Renato Lenzi; James L Abbruzzese
Metastatic patterns in adenocarcinoma.
Cancer 2006;106(7):1624-33.
2001: Martin N Raber
A patient's perspective on cancer-related fatigue.
Cancer 2001;92(6 Suppl):1662-3.
1999: Kenneth R Hess; MC Abbruzzese; Renato Lenzi; Martin N Raber; James L Abbruzzese
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3403-10.
1998: N Touroutoglou; D Gravel; Martin N Raber; W Plunkett; James L Abbruzzese
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(9):1003-8.
1998: JP Ayoub; Kenneth R Hess; MC Abbruzzese; Renato Lenzi; Martin N Raber; James L Abbruzzese
Unknown primary tumors metastatic to liver.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2105-12.
1998: Renato Lenzi; E Edmund Kim; Martin N Raber; James L Abbruzzese
Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(2):213-6.
1997: Renato Lenzi; Kenneth R Hess; MC Abbruzzese; Martin N Raber; Nelson G Ordoñez; James L Abbruzzese
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):2056-66.
1996: James L Abbruzzese; Timothy Madden; S M Sugarman; A L Ellis; SM Loughlin; Kenneth R Hess; Robert A Newman; Leonard A Zwelling; Martin N Raber
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(9):1489-97.
1996: Andrzej P Kudelka; Damras Tresukosol; Creighton L Edwards; Ralph S Freedman; Charles Levenback; P Chantarawiroj; C Gonzalez de Leon; E Edmund Kim; Timothy Madden; B Wallin; M Hord; Claire F Verschraegen; Martin N Raber; John J Kavanagh
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1552-7.
1996: James L Abbruzzese; M C Abbruzzese; Renato Lenzi; Martin N Raber; Kenneth R Hess
Are time or intensity factors important to the definition of metastases of unknown origin?
Journal of the National Cancer Institute 1996;88(7):462-3.
1996: Roman Perez-Soler; Frank V Fossella; Bonnie S Glisson; Jin S Lee; WK Murphy; Dong M Shin; Bonnie L Kemp; J Jack Lee; J Kane; R A Robinson; Scott M Lippman; Jonathan M Kurie; M H Huber; Martin N Raber; Waun Ki Hong
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):503-13.
1996: Terry L Smith; J Jack Lee; Hagop M Kantarjian; Sewa S Legha; Martin N Raber
Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):287-95.
1996: K Hoffman; Frankie A Holmes; Giuseppe Fraschini; L Esparza; Debra Frye; Martin N Raber; Robert A Newman; Gabriel N Hortobagyi
Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.
Cancer chemotherapy and pharmacology 1996;37(3):254-8.
1995: James L Abbruzzese; MC Abbruzzese; Renato Lenzi; Kenneth R Hess; Martin N Raber
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):2094-103.
1995: Jin S Lee; Robert A Newman; Scott M Lippman; Frank V Fossella; M Calayag; Martin N Raber; I H Krakoff; Waun Ki Hong
Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1501-8.
1994: James L Abbruzzese; MC Abbruzzese; Kenneth R Hess; Martin N Raber; Renato Lenzi; P Frost
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(6):1272-80.
1994: Dong M Shin; P Y Holoye; A Forman; Rodger Winn; Roman Perez-Soler; Shaker R Dakhil; J Rosenthal; Martin N Raber; Waun Ki Hong
Phase II clinical trial of didemnin B in previously treated small cell lung cancer.
Investigational new drugs 1994;12(3):243-9.
1993: James L Abbruzzese; Renato Lenzi; Martin N Raber; Sen Pathak; P Frost
The biology of unknown primary tumors.
Seminars in oncology 1993;20(3):238-43.
1993: Jin S Lee; Robert A Newman; Scott M Lippman; M H Huber; T Minor; Martin N Raber; I H Krakoff; Waun Ki Hong
Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):959-66.
1993: WK Murphy; Frank V Fossella; RJ Winn; Dong M Shin; H E Hynes; H M Gross; E Davilla; J Leimert; H Dhingra; Martin N Raber
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.
Journal of the National Cancer Institute 1993;85(5):384-8.
1993: Dah H Ho; Richard Pazdur; N S Brown; W P Covington; Martin N Raber; I H Krakoff
Clinical pharmacology of 11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo (7.4.1.0(2,7).0(10,12) tetradeca-2,4,6-trien-6,9-diyl diacetate (FK 973).
Anticancer research 1993;13(2):343-6.
1993: Richard L Theriault; I A Cohen; L Esparza; C Kowal; Martin N Raber
Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4- butanediamine-N,N1) platinum in patients with metastatic solid tumors.
Cancer chemotherapy and pharmacology 1993;31(4):333-7.
1993: Renato Lenzi; Martin N Raber; P Frost; S Schmidt; James L Abbruzzese
Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin.
European journal of cancer (Oxford, England : 1990) 1993;29A(11):1634.
1992: Dah H Ho; W P Covington; Richard Pazdur; N S Brown; J Kuritani; Robert A Newman; Martin N Raber; I H Krakoff
Clinical pharmacology of combined oral uracil and ftorafur.
Drug metabolism and disposition: the biological fate of chemicals 1992;20(6):936-40.
1992: Frank V Fossella; RJ Winn; P Y Holoye; B Hallinan; Martin N Raber; K Hoelzer; J A Young; J Readling; B Bowers; Waun Ki Hong
Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.
Investigational new drugs 1992;10(4):331-5.
1992: J A Benvenuto; Robert A Newman; Gary Bignami; T J Raybould; Martin N Raber; L Esparza; Ronald S Walters
Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer.
Investigational new drugs 1992;10(2):113-7.
1992: Martin N Raber; Robert A Newman; B M Newman; R C Gaver; L P Schacter
Phase I trial and clinical pharmacology of elsamitrucin.
Cancer research 1992;52(6):1406-10.
1992: J A Benvenuto; W Ayele; Sewa S Legha; Martin N Raber; C Nicaise; Robert A Newman
Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine.
Anti-cancer drugs 1992;3(1):19-23.
1992: R Amato; D Ho; S Schmidt; I H Krakoff; Martin N Raber
Phase I trial of a 72-h continuous-infusion schedule of fazarabine.
Cancer chemotherapy and pharmacology 1992;30(4):321-4.
1991: Frankie A Holmes; Ronald S Walters; Richard L Theriault; A D Forman; L K Newton; Martin N Raber; Aman U Buzdar; Debra Frye; Gabriel N Hortobagyi
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
Journal of the National Cancer Institute 1991;83(24):1797-805.
1991: Richard Pazdur; Dah H Ho; K Daugherty; W T Bradner; I H Krakoff; Martin N Raber
Phase I trial of FK973: description of a delayed vascular leak syndrome.
Investigational new drugs 1991;9(4):377-82.
1991: Frank V Fossella; RJ Winn; P Y Holoye; Martin N Raber; L Holden; R Belt; H Allen; B Hallinan; K Harper
Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma.
Investigational new drugs 1991;9(4):375-6.
1991: Martin N Raber; J Faintuch; James L Abbruzzese; C Sumrall; P Frost
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(7):519-20.
1991: SD Huan; Sewa S Legha; Martin N Raber; I H Krakoff
Phase I studies of trimetrexate using single and weekly dose schedules.
Investigational new drugs 1991;9(2):199-206.
1991: Dah H Ho; N Brown; J R Lin; W Covington; Robert A Newman; Martin N Raber; R Amato; S Schmidt; I H Krakoff
Clinical pharmacology of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion.
Drug metabolism and disposition: the biological fate of chemicals 1991;19(3):643-7.
1991: James L Abbruzzese; R Grunewald; E A Weeks; D Gravel; T Adams; B Nowak; Shin Mineishi; P Tarassoff; W Satterlee; Martin N Raber
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(3):491-8.
1991: Dong M Shin; A M Kramer; I W Dimery; Martin N Raber; Michael S Ewer; Waun Ki Hong
Phase II clinical trial of 4'-O-tetrahydropyranyl-adriamycin (THP-adriamycin) in recurrent squamous cell carcinoma of the head and neck.
Investigational new drugs 1991;9(1):89-91.
1991: H M Dhingra; WK Murphy; RJ Winn; Martin N Raber; Waun Ki Hong
Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma.
Investigational new drugs 1991;9(1):69-72.
1991: Dong M Shin; P Y Holoye; WK Murphy; A Forman; Sozos Ch Papasozomenos; Waun Ki Hong; Martin N Raber
Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.
Cancer chemotherapy and pharmacology 1991;29(2):145-9.
1990: L G Sandles; Ralph S Freedman; Martin N Raber; John Kavanagh; Creighton L Edwards; W R Scott; J Taylor Wharton
Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies.
Gynecologic oncology 1990;39(2):139-45.
1990: Roman Perez-Soler; Gabriel Lopez-Berestein; J Lautersztain; S al-Baker; K Francis; D Macias-Kiger; Martin N Raber; Abdul R Khokhar
Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
Cancer research 1990;50(14):4254-9.
1990: Sewa S Legha; Sigrid E Ring; Nicholas Papadopoulos; Martin N Raber; Robert S Benjamin
A phase II trial of taxol in metastatic melanoma.
Cancer 1990;65(11):2478-81.
1990: P Y Holoye; Bonnie S Glisson; Jin S Lee; H M Dhingra; WK Murphy; T Umsawasdi; J K Levy; D Jeffries; Martin N Raber; Waun Ki Hong
Ifosfamide with mesna uroprotection in the management of lung cancer.
American journal of clinical oncology 1990;13(2):148-55.
1990: Jaffer A Ajani; S R Welch; Martin N Raber; W S Fields; I H Krakoff
Comprehensive criteria for assessing therapy-induced toxicity.
Cancer investigation 1990;8(2):147-59.
1990: James L Abbruzzese; R Amato; S Schmidt; Martin N Raber; P Frost
Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.
Cancer chemotherapy and pharmacology 1990;26(3):159-62.
1990: P Y Holoye; D G Jeffries; H M Dhingra; Frankie A Holmes; Martin N Raber; M S Engineer; Robert A Newman
Intrapleural etoposide for malignant effusion.
Cancer chemotherapy and pharmacology 1990;26(2):147-50.
1989: James L Abbruzzese; A Weeks; Martin N Raber; D Gravel; R A DuBrow; Bernard Levin; J Grem; H G Chun
Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer.
Journal of the National Cancer Institute 1989;81(23):1840-2.
1989: James L Abbruzzese; S Schmidt; Martin N Raber; J K Levy; A M Castellanos; Sewa S Legha; I H Krakoff
Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity.
Investigational new drugs 1989;7(2-3):195-201.
1989: Martin N Raber; Robert A Newman; K Lu; Sewa S Legha; C Gorski; Robert S Benjamin; I H Krakoff
Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin).
Cancer chemotherapy and pharmacology 1989;23(5):311-5.
1988: J Lautersztain; C Santos; Martin N Raber
Multiple primary malignant tumors.
American journal of clinical oncology 1988;11(4):506-10.
1987: Sewa S Legha; Sigrid E Ring; Martin N Raber; T B Felder; Robert A Newman; I H Krakoff
Phase I clinical investigation of benzisoquinolinedione.
Cancer treatment reports 1987;71(12):1165-9.
1987: Martin N Raber; F Adams; John Kavanagh; Sewa S Legha; I Dimery; I Krakoff
Phase I trial of caracemide using bolus and infusion schedules.
Cancer treatment reports 1987;71(4):349-52.